<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204490</url>
  </required_header>
  <id_info>
    <org_study_id>03-260</org_study_id>
    <secondary_id>UTMB GCRC #635</secondary_id>
    <secondary_id>R01CA095545</secondary_id>
    <secondary_id>M01RR000073</secondary_id>
    <secondary_id>1UL1RR029876-01</secondary_id>
    <nct_id>NCT00204490</nct_id>
  </id_info>
  <brief_title>Soy Isoflavones and Breast Cancer Risk Reduction</brief_title>
  <official_title>Mammographic Density and Soy Isoflavones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Soy consumption has been associated with reduced risk for developing breast cancer. Soy&#xD;
      contains isoflavones which are weak estrogens. The roles of soy isoflavones in reducing&#xD;
      breast cancer risk are currently unclear. Breast density has been considered as a breast&#xD;
      cancer risk marker. We hypothesize that because isoflavones have estrogen-like activities,&#xD;
      breast density and possibly bone density will be lower in women on soy-isoflavones.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind study, with two arms and 100 women in each arm.&#xD;
      Premenopausal women will be recruited and randomly allocated to take one of the two different&#xD;
      dietary supplements in pills daily for 2 years. The two supplements are soy isoflavones&#xD;
      (treatment) and placebo (carbohydrates). Both treatment and placebo pills will contain&#xD;
      multi-vitamins and minerals. Multiple blood, urine, and breast fluid samples will be obtained&#xD;
      before and during the dietary supplement periods and analyzed for biomarkers of breast cancer&#xD;
      risk. At baseline and after the intervention period, breast density and bone density will be&#xD;
      assessed by radiologic techniques. The efficacy of the dietary intervention will be&#xD;
      determined by comparing mean changes of serum markers for breast cancer risk,dense breast&#xD;
      tissue, and bone mineral density over the two year dietary intervention period in the two&#xD;
      supplement groups with adjustment for baseline values and individual patient characteristics&#xD;
      of interest. We predict that 2 years of soy isoflavone supplement will reduce breast density,&#xD;
      which may be explained by individual changes in serum markers of breast cancer risk.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2004</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One group received soy isoflavones (60 mg daidzein, 60 mg gensitein and 16.6 mg glycitein, all as aglycone equivalent) Another group, carbohydrate filler</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Research pharmacist dispensed study pills according to a pre-generated randomization list and were blinded to all other aspects of the study protocol.&#xD;
Subjects, research staff, investigators, and statistician all were blinded to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Breast density</measure>
    <time_frame>one or two years after dietary supplements</time_frame>
    <description>Amount or percentage of fibroglandular breast tissue in a breast as measured by digital mammography or by magnetic resonance imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bone density</measure>
    <time_frame>one or two years after dietary supplement</time_frame>
    <description>Bone mineral density of whole body, hip and spine as measured by dual x-ray absorptiometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>soy isoflavones</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>carbohydrates (maltodextrin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>isoflavones</intervention_name>
    <description>soy isoflavones: Each tablet contains 246 mg Novasoy, 676 mg calcium, 15 mg riboflavin, and other innert materials to a total weight of 1000 mg. Subject takes two isoflavone tablets plus 1 multi-vitamin per day for five days per week for upto 2 years.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Isoflavone pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>carbohydrate</intervention_name>
    <description>carbohydrate: 246 mg maltodextrin, 676 mg calcium, 15 mg riboflavin and other innert ingredients to a total weight of 1000 mg per tablet. subject takes two tablets plus one multivitamin per day for five days per week for upto 2 years.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy premenopausal women&#xD;
&#xD;
          -  30 to 42 years old&#xD;
&#xD;
          -  normal mammograms&#xD;
&#xD;
          -  regular menstrual cycles&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  abnormal mammograms&#xD;
&#xD;
          -  first degree relatives with breast cancer&#xD;
&#xD;
          -  pregnant or lactating&#xD;
&#xD;
          -  peri- or post-menopause&#xD;
&#xD;
          -  breast augmentation, reduction or lifting&#xD;
&#xD;
          -  on oral contraceptive medications or exogenous hormones&#xD;
&#xD;
          -  medically prescribed diets&#xD;
&#xD;
          -  allergic reaction to soy products&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee-Jane W Lu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Teas Medical Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Clinical Reserach Center, The University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0264</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>soy</keyword>
  <keyword>isoflavones</keyword>
  <keyword>phytoestrogens</keyword>
  <keyword>prevention</keyword>
  <keyword>mammographic density</keyword>
  <keyword>bone density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

